Fig. 2. CV2CoV elicits high levels of binding and neutralizing antibody responses in macaques.
Animals (n = 6 per group) were vaccinated twice with 12 µg of CVnCoV or CV2CoV on day 0 and on day 28 or remained untreated as negative controls (sham). a, b, Titres of RBD-binding antibodies (a) and pseudovirus neutralizing antibodies (NAb) against the ancestral SARS-CoV-2 strain (b) were evaluated at different time points after the first (weeks 0, 1, 2 and 4) and second (weeks 5, 6 and 8) vaccinations. c, d, Sera collected on day 42 (week 6) were analysed for pseudovirus (c) and live-virus (d) neutralizing antibody titres against virus with the D614G mutation and the B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta) variants. e, Sera collected from non-human primates immunized with 12 µg of CVnCoV or 30 µg of BNT162b2 on day 35 (week 5) after boosting were analysed for pseudovirus neutralizing antibody titres against the ancestral WA/2020 (WT) strain. Each dot represents an individual animal and bars depict the median; the dashed line shows the limit of detection.